KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Gains from Sales and Divestitures (2019 - 2022)

Historic Gains from Sales and Divestitures for Pacific Biosciences Of California (PACB) over the last 4 years, with Q4 2022 value amounting to $2.6 million.

  • Pacific Biosciences Of California's Gains from Sales and Divestitures rose 4360.4% to $2.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.6 million, marking a year-over-year increase of 4360.4%. This contributed to the annual value of $2.6 million for FY2022, which is 4360.4% up from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Gains from Sales and Divestitures of $2.6 million as of Q4 2022, which was up 4360.4% from $2.4 million recorded in Q3 2022.
  • In the past 5 years, Pacific Biosciences Of California's Gains from Sales and Divestitures registered a high of $2.6 million during Q4 2022, and its lowest value of $2026.0 during Q2 2022.
  • Moreover, its 4-year median value for Gains from Sales and Divestitures was $938000.0 (2020), whereas its average is $1.1 million.
  • In the last 5 years, Pacific Biosciences Of California's Gains from Sales and Divestitures surged by 39019.61% in 2020 and then plummeted by 9986.39% in 2022.
  • Quarter analysis of 4 years shows Pacific Biosciences Of California's Gains from Sales and Divestitures stood at $204000.0 in 2019, then soared by 390.2% to $1.0 million in 2020, then skyrocketed by 79.8% to $1.8 million in 2021, then soared by 43.6% to $2.6 million in 2022.
  • Its Gains from Sales and Divestitures stands at $2.6 million for Q4 2022, versus $2.4 million for Q3 2022 and $2026.0 for Q2 2022.